Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson’s Disease Targeting Neuroinflammation
Abstract
:1. Introduction
2. Results
2.1. α-Synuclein Induced Microglial Activation in Mouse BV-2 Cells
2.2. Anti-Inflammatory Potentials of Test Compounds and Herbs in BV-2 Microglia
2.3. Cytokine Expression Profiles in α-Synuclein-Stimulated BV-2 Cells
2.4. SH-SY5Y Cells with Induced A53T α-Synuclein-GFP Expression
2.5. Reduction of α-Synuclein Aggregation of the Test Compounds/Herbs in A53T SNCA-GFP SH-SY5Y Cells
2.6. Promotion of Neurite Outgrowth and Neuronal Survival of the Test Compounds/Herbs in A53T SNCA-GFP SH-SY5Y Cells
2.7. Downregulation of NLRP1/3 Inflammasome Pathways by Test Compounds/Herbs in A53T SNCA-GFP SH-SY5Y Cells
3. Discussion
4. Materials and Methods
4.1. Compounds, Herbs, and Cell Culture
4.2. Cell Proliferation Assay
4.3. Detection of BV-2 Microglial Activation
4.4. Mouse Inflammation Antibody Array
4.5. Cytokine qRT-PCR Assay
4.6. Cytokine ELISA
4.7. A53T SNCA-GFP Construct
4.8. A53T SNCA-GFP SH-SY5Y Cells
4.9. Tyrosine Hydroxylase Staining
4.10. α-Synuclein Aggregation and Neurite Outgrowth Analyses
4.11. Caspase 1 and 3 Activities and LDH Release Assays
4.12. ROS Analysis
4.13. Western Blot Analysis for Inflammasome Signaling
4.14. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Halbach, O.; Schober, A.; Krieglstein, K. Genes, proteins, and neurotoxins involved in Parkinson’s disease. Progress. Neurobiol. 2004, 73, 151–177. [Google Scholar] [CrossRef]
- Lill, C.M. Genetics of Parkinson’s disease. Mol. Cell Probes 2016, 30, 386–396. [Google Scholar] [CrossRef] [PubMed]
- Trinh, J.; Farrer, M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 2013, 9, 445–454. [Google Scholar] [CrossRef] [PubMed]
- Ramanan, V.K.; Saykin, A.J. Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. Am. J. Neurodegener. Dis. 2013, 2, 145–175. [Google Scholar]
- Holmans, P.; Moskvina, V.; Jones, L.; Sharma, M.; International Parkinson’s Disease Genomics Consortium; Vedernikov, A.; Buchel, F.; Saad, M.; Bras, J.M.; Bettella, F.; et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson’s disease. Hum. Mol. Genet. 2013, 22, 1039–1049. [Google Scholar] [CrossRef] [PubMed]
- McGeer, P.L.; McGeer, E.G. Glial reactions in Parkinson’s disease. Mov. Disord. 2008, 23, 474–483. [Google Scholar] [CrossRef] [PubMed]
- Flood, P.M.; Qian, L.; Peterson, L.J.; Zhang, F.; Shi, J.S.; Gao, H.M.; Hong, J.S. Transcriptional factor NF-κB as a target for therapy in Parkinson’s disease. Parkinsons Disease 2011, 2011, 216298. [Google Scholar] [CrossRef] [Green Version]
- Phani, S.; Loike, J.D.; Przedborski, S. Neurodegeneration and inflammation in Parkinson’s disease. Parkinsonism Relat. Disord. 2012, 18, S207–S209. [Google Scholar] [CrossRef]
- Sanchez-Guajardo, V.; Barnum, C.J.; Tansey, M.G.; Romero-Ramos, M. Neuroimmunological processes in Parkinson’s disease and their relation to α-synuclein: Microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013, 5, 113–139. [Google Scholar] [CrossRef] [Green Version]
- Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; et al. Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB J. 2005, 19, 533–542. [Google Scholar] [CrossRef]
- Couch, Y.; Alvarez-Erviti, L.; Sibson, N.R.; Wood, M.J.A.; Anthony, D.C. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J. Neuroinflammation 2011, 8, 166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomé, C.M.L.; Tyson, T.; Rey, N.L.; Grathwohl, S.; Britschgi, M.; Brundin, P. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease. Mol. Neurobiol. 2013, 47, 561–574. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sampson, T.R.; Debelius, J.W.; Thron, T.; Janssen, S.; Shastri, G.G.; Ilhan, Z.E.; Challis, C.; Schretter, C.E.; Rocha, S.; Gradinaru, V.; et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 2016, 167, 1469–1480.e12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ramsey, C.P.; Tansey, M.G. A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson’s disease and potential molecular targets. Exp. Neurol. 2014, 256, 126–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, H.; Jacobs, E.; Schwarzschild, M.A.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Nonsteroidal anti-inflammatory drug use and the risk for Parkinson’s disease. Ann. Neurol. 2005, 58, 963–967. [Google Scholar] [CrossRef] [PubMed]
- Bassani, T.B.; Vital, M.A.; Rauh, L.K. Neuroinflammation in the pathophysiology of Parkinson’s disease and therapeutic evidence of anti-inflammatory drugs. Arq. Neuro-Psiquiatr. 2015, 73, 616–623. [Google Scholar] [CrossRef] [PubMed]
- Schroder, K.; Tschopp, J. The inflammasomes. Cell 2010, 140, 821–832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panicker, N.; Sarkar, S.; Harischandra, D.S.; Neal, M.; Kam, T.I.; Jin, H.; Saminathan, H.; Langley, M.; Charli, A.; Samidurai, A.; et al. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. J. Exp. Med. 2019, 216, 1411–1430. [Google Scholar] [CrossRef]
- Meng, X.F.; Wang, X.L.; Tian, X.J.; Yang, Z.H.; Chu, G.P.; Zhang, J.; Li, M.; Shi, J.; Zhang, C. Nod-like receptor protein 1 inflammasome mediates neuron injury under high glucose. Mol. Neurobiol. 2014, 49, 673–684. [Google Scholar] [CrossRef]
- O’Neill, L.A.J. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Curr. Top. Microbiol. Immunol. 2002, 270, 47–61. [Google Scholar]
- Ghosh, S.; Hayden, M.S. Celebrating 25 years of NF-κB research. Immunol. Rev. 2012, 246, 5–13. [Google Scholar] [CrossRef] [PubMed]
- Huang, G.; Shi, L.Z.; Chi, H. Regulation of JNK and p38 MAPK in the immune system: Signal integration, propagation and termination. Cytokine 2009, 48, 161–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Y.; Kim, S.C.; Yu, T.; Yi, Y.S.; Rhee, M.H.; Sung, G.H.; Yoo, B.C.; Cho, J.Y. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediat. Inflamm. 2014, 2014, 352371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babon, J.J.; Varghese, L.N.; Nicola, N.A. Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 2014, 26, 13–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, I.C.; Lin, T.H.; Hsieh, Y.H.; Chao, C.Y.; Wu, Y.R.; Chang, K.H.; Lee, M.C.; Lee-Chen, G.J.; Chen, C.M. Formulated Chinese medicine Shaoyao Gancao Tang reduces tau aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation. Oxidative Med. Cell. Longev. 2018, 2018, 9595741. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.M.; Chen, W.L.; Hung, C.T.; Lin, T.H.; Lee, M.C.; Chen, I.C.; Lin, C.H.; Chao, C.Y.; Wu, Y.R.; Chang, K.H.; et al. Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models. Aging 2019, 11, 986–1007. [Google Scholar] [CrossRef]
- Chen, C.M.; Weng, Y.T.; Chen, W.L.; Lin, T.H.; Chao, C.Y.; Lin, C.H.; Chen, I.C.; Lee, L.C.; Lin, H.Y.; Wu, Y.R.; et al. Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2-ARE pathways in cell models of spinocerebellar ataxia 3. Free Radic. Biol. Med. 2014, 71, 339–350. [Google Scholar] [CrossRef]
- Chiu, Y.J.; Lee, C.M.; Lin, T.H.; Lin, H.Y.; Lee, S.Y.; Mesri, M.; Chang, K.H.; Lin, J.Y.; Lee-Chen, G.J.; Chen, C.M. Chinese herbal medicine Glycyrrhiza inflata reduces Aβ aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation. Am. J. Chin. Med. 2018, 46, 1535–1559. [Google Scholar] [CrossRef]
- Kim, S.H.; Hong, J.H.; Lee, J.E.; Lee, Y.C. 18β-Glycyrrhetinic acid, the major bioactive component of Glycyrrhizae Radix, attenuates airway inflammation by modulating Th2 cytokines, GATA-3, STAT6, and Foxp3 transcription factors in an asthmatic mouse model. Environ. Toxicol. Pharmacol. 2017, 52, 99–113. [Google Scholar] [CrossRef]
- Chiu, Y.J.; Hsieh, Y.H.; Lin, T.H.; Lee, G.C.; Hsieh-Li, H.M.; Sun, Y.C.; Chen, C.M.; Chang, K.H.; Lee-Chen, G.J. Novel compound VB-037 inhibits Aβ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer’s disease. Neurochem. Int. 2019, 125, 175–186. [Google Scholar] [CrossRef] [PubMed]
- SSaliba, W.; Bonifacino, T.; Serchov, T.; Bonanno, G.; de Oliveira, A.C.P.; Fiebich, B.L. Neuroprotective effect of AM404 against NMDA-induced hippocampal excitotoxicity. Front. Cell. Neurosci. 2019, 13, 566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marques, O.; Outeiro, T.F. α-Synuclein: From secretion to dysfunction and death. Cell Death Dis. 2012, 3, e350. [Google Scholar] [CrossRef] [PubMed]
- McGeer, P.L.; Kawamata, T.; Walker, D.G.; Akiyama, H.; Tooyama, I.; McGeer, E.G. Microglia in degenerative neurological disease. Glia 1993, 7, 84–92. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.M.; Lin, C.H.; Wu, Y.R.; Yen, C.Y.; Huang, Y.T.; Lin, J.L.; Lin, C.Y.; Chen, W.L.; Chao, C.Y.; Lee-Chen, G.J.; et al. Lactulose and melibiose inhibit α-synuclein aggregation and up-regulate autophagy to reduce neuronal vulnerability. Cells 2020, 9, 1230–1251. [Google Scholar] [CrossRef] [PubMed]
- Oshinbolu, S.; Shah, R.; Finka, G.; Molloy, M.; Uden, M.; Bracewell, D.G. Evaluation of fluorescent dyes to measure protein aggregation within mammalian cell culture supernatants. J. Chem. Technol. Biotechnol. 2018, 93, 909–917. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.J.; Lee, K.; Im, H. α-Synuclein modulates neurite outgrowth by interacting with SPTBN1. Biochem. Biophys. Res. Commun. 2012, 424, 497–502. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.; Lim, J.; Bang, Y.; Moon, J.; Kwon, M.S.; Hong, J.T.; Jeon, J.; Seo, H.; Choi, H.J. α-Synuclein suppresses retinoic acid-induced neuronal differentiation by targeting the glycogen synthase kinase-3β/β-catenin signaling pathway. Mol. Neurobiol. 2018, 55, 1607–1619. [Google Scholar] [CrossRef]
- Broz, P.; Dixit, V.M. Inflammasomes: Mechanism of assembly, regulation and signaling. Nat. Rev. Immunol. 2016, 16, 407–420. [Google Scholar] [CrossRef]
- Codolo, G.; Plotegher, N.; Pozzobon, T.; Brucale, M.; Tessari, I.; Bubacco, L.; de Bernard, M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS ONE 2013, 8, e55375. [Google Scholar] [CrossRef] [Green Version]
- Yap, J.K.Y.; Pickard, B.S.; Chan, E.W.; Gan, S.Y. The role of neuronal NLRP1 inflammasome in Alzheimer’s disease: Bringing neurons into the neuroinflammation game. Mol. Neurobiol. 2019, 56, 7741–7753. [Google Scholar] [CrossRef]
- Goldstein, D.M.; Gabriel, T. Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 2005, 5, 1017–1029. [Google Scholar] [CrossRef] [PubMed]
- Cui, J.; Zhang, M.; Zhang, Y.Q.; Xu, Z.H. JNK pathway: Diseases and therapeutic potential. Acta Pharmacol. Sin. 2007, 28, 601–608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Renard, P.; Zachary, M.D.; Bougelet, C.; Mirault, M.E.; Haegeman, G.; Remacle, J.; Raes, M. Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor κB activation. Biochem. Pharmacol. 1997, 53, 149–160. [Google Scholar] [CrossRef]
- Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295. [Google Scholar] [CrossRef] [PubMed]
- Gelders, G.; Baekelandt, V.; van der Perren, A. Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J. Immunol. Res. 2018, 2018, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Mirza, M.U.; Mirza, A.H.; Ghori, N.U.; Ferdous, S. Glycyrrhetinic acid and E. resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: A pharmacoinformatics study. Drug Des. Dev. Ther. 2014, 9, 187–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ojha, S.; Javed, H.; Azimullah, S.; Khair, S.B.A.; Haque, M.E. Glycyrrhizic acid attenuates neuroinflammation and oxidative stress in rotenone model of Parkinson’s disease. Neurotox. Res. 2016, 29, 275–287. [Google Scholar] [CrossRef]
- Kummer, J.A.; Broekhuizen, R.; Everett, H.; Agostini, L.; Kuijk, L.; Martinon, F.; van Bruggen, R.; Tschopp, J. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J. Histochem. Cytochem. 2007, 55, 443–452. [Google Scholar] [CrossRef] [Green Version]
- Voet, S.; Srinivasan, S.; Lamkanfi, M.; van Loo, G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol. Med. 2019, 11, e10248. [Google Scholar] [CrossRef]
- Kaushal, V.; Dye, R.; Pakavathkumar, P.; Foveau, B.; Flores, J.; Hyman, B.; Ghetti, B.; Koller, B.H.; LeBlanc, A.C. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-β production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 2015, 22, 1676–1686. [Google Scholar] [CrossRef] [Green Version]
- McLarnon, J.G.; Ryu, J.K.; Walker, D.G.; Choi, H.B. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-β peptide-treated microglia and in peptide-injected rat hippocampus. J. Neuropathol. Exp. Neurol. 2006, 65, 1090–1097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- FSáez-Orellana; Fuentes-Fuentes, M.C.; Godoy, P.A.; Silva-Grecchi, T.; Panes, J.D.; Guzmán, L.; Yévenes, G.E.; Gavilán, J.; Egan, T.M.; Aguayo, L.G.; et al. P2X receptor overexpression induced by soluble oligomers of amyloid β peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer’s disease. Neuropharmacology 2018, 128, 366–378. [Google Scholar]
- Wang, W.; Nguyen, L.T.; Burlak, C.; Chegini, F.; Guo, F.; Chataway, T.; Ju, S.; Fisher, O.S.; Miller, D.W.; Datta, D.; et al. Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein. Proc. Natl. Acad. Sci. USA 2016, 113, 9587–9592. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tschopp, J.; Schroder, K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production. Nat. Rev. Immunol. 2010, 10, 210–215. [Google Scholar] [CrossRef]
- Minutoli, L.; Puzzolo, D.; Rinaldi, M.; Irrera, N.; Marini, H.; Arcoraci, V.; Bitto, A.; Crea, G.; Pisani, A.; Squadrito, F.; et al. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury. Oxidative Med. Cell. Longev. 2016, 2016, 2183026. [Google Scholar] [CrossRef]
- Xu, X.; Zhang, L.; Ye, X.; Hao, Q.; Zhang, T.; Cui, G.; Yu, M. Nrf2/ARE pathway inhibits ROS-induced NLRP3 inflammasome activation in BV2 cells after cerebral ischemia reperfusion. Inflamm. Res. 2018, 67, 57–65. [Google Scholar] [CrossRef]
- Ferrari, C.C.; Godoy, M.C.P.; Tarelli, R.; Chertoff, M.; Depino, A.M.; Pitossi, F.J. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. Neurobiol. Dis. 2006, 24, 183–193. [Google Scholar] [CrossRef]
- Godoy, M.C.P.; Ferrari, C.C.; Pitossi, F.J. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J. Neuroimmunol. 2010, 222, 29–39. [Google Scholar] [CrossRef]
- Mogi, M.; Harada, M.; Kondo, T.; Riederer, P.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180, 147–150. [Google Scholar] [CrossRef]
- Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson’s disease. J. Neural Transm. Suppl. 2000, 58, 143–151. [Google Scholar]
- Koprich, J.B.; Reske-Nielsen, C.; Mithal, P.; Isacson, O. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J. Neuroinflammation 2008, 5, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dhanasekaran, D.N.; Reddy, E.P. JNK signaling in apoptosis. Oncogene 2008, 27, 6245–6251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhuang, W.; Cai, M.; Li, W.; Chen, C.; Wang, Y.; Lv, E.; Fu, W. Polyphenols from Toona sinensiss seeds alleviate neuroinflammation induced by 6-hydroxydopamine through suppressing p38 MAPK signaling pathway in a rat model of Parkinson’s disease. Neurochem. Res. 2020, 45, 2052–2064. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.S.; Rai, S.N.; Birla, H.; Zahra, W.; Rathore, A.S.; Singh, S.P. NF-κB-mediated neuroinflammation in Parkinson’s disease and potential therapeutic effect of polyphenols. Neurotox. Res. 2020, 37, 491–507. [Google Scholar] [CrossRef] [PubMed]
- Ringheim, G.E.; Burgher, K.L.; Heroux, J.A. Interleukin-6 mRNA expression by cortical neurons in culture: Evidence for neuronal sources of interleukin-6 production in the brain. J. Neuroimmunol. 1995, 63, 113–123. [Google Scholar] [CrossRef]
- März, P.; Cheng, J.G.; Gadient, R.A.; Patterson, P.H.; Stoyan, T.; Otten, U.; Rose-John, S. Sympathetic neurons can produce and respond to interleukin 6. Proc. Natl. Acad. Sci. USA 1998, 95, 3251–3256. [Google Scholar] [CrossRef] [Green Version]
- Sallmann, S.; Jüttler, E.; Prinz, S.; Petersen, N.; Knopf, U.; Weiser, T.; Schwaninger, M. Induction of interleukin-6 by depolarization of neurons. J. Neurosci. 2000, 20, 8637–8642. [Google Scholar] [CrossRef] [Green Version]
- Haim, L.B.; Ceyzériat, K.; Carrillo-de Sauvage, M.A.; Aubry, F.; Auregan, G.; Guillermier, M.; Ruiz, M.; Petit, F.; Houitte, D.; Faivre, E.; et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer’s and Huntington’s diseases. J. Neurosci. 2015, 35, 2817–2829. [Google Scholar] [CrossRef]
- Chen, X.; Hu, Y.; Cao, Z.; Liu, Q.; Cheng, Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Front. Immunol. 2018, 9, 2122. [Google Scholar] [CrossRef] [Green Version]
- Green, H.F.; Khosousi, S.; Svenningsson, P. Plasma IL-6 and IL-17A correlate with severity of motor and non-motor symptoms in Parkinson’s disease. J. Parkinsons Dis. 2019, 9, 705–709. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Dongwei, Z.; Zhang, Z.; Qu, X.; Bao, K.; Lu, G.; Duan, J. miR-let-7a suppresses α-synuclein-induced microglia inflammation through targeting STAT3 in Parkinson’s disease. Biochem. Biophys. Res. Commun. 2019, 519, 740–746. [Google Scholar] [CrossRef] [PubMed]
- He, D.; Chen, S.; Xiao, Z.; Wu, H.; Zhou, G.; Xu, C.; Chang, Y.; Li, Y.; Wang, G.; Xie, M. Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson’s disease model in vitro. Folia Histochem. Cytobiol. 2020, 58, 127–134. [Google Scholar] [CrossRef] [PubMed]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Påhlman, S.; Odelstad, L.; Larsson, E.; Grotte, G.; Nilsson, K. Phenotypic changes of human neuroblastoma cells in culture induced by 12-O-tetradecanoyl-phorbol-13-acetate. Int. J. Cancer 1981, 28, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Luk, K.C.; Song, C.; O’Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M.Y. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 2009, 106, 20051–20056. [Google Scholar] [CrossRef] [Green Version]
Cytokine | Fold Change (+ vs. - α-Syn) | Fold Change (+ VB-037/α-Syn vs. + α-Syn) | Fold Change (+ Glycyrrhetic/α-Syn vs. + α-Syn) |
---|---|---|---|
IL-1α | 9.7 | 6.8 | 8.0 |
IL-1β | 2.6 | 0.8 | 0.4 |
TNF-α | 3.5 | 0.8 | 3.1 |
IFN-γ | 1.7 | 1.2 | 1.0 |
GM-CSF | 5.2 | 1.6 | 2.8 |
IL-6 | 104.9 | 65.9 | 73.7 |
G-CSF | 97.7 | 42.9 | 54.0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, C.-M.; Yen, C.-Y.; Chen, W.-L.; Lin, C.-H.; Wu, Y.-R.; Chang, K.-H.; Lee-Chen, G.-J. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson’s Disease Targeting Neuroinflammation. Int. J. Mol. Sci. 2021, 22, 1062. https://doi.org/10.3390/ijms22031062
Chen C-M, Yen C-Y, Chen W-L, Lin C-H, Wu Y-R, Chang K-H, Lee-Chen G-J. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson’s Disease Targeting Neuroinflammation. International Journal of Molecular Sciences. 2021; 22(3):1062. https://doi.org/10.3390/ijms22031062
Chicago/Turabian StyleChen, Chiung-Mei, Chien-Yu Yen, Wan-Ling Chen, Chih-Hsin Lin, Yih-Ru Wu, Kuo-Hsuan Chang, and Guey-Jen Lee-Chen. 2021. "Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson’s Disease Targeting Neuroinflammation" International Journal of Molecular Sciences 22, no. 3: 1062. https://doi.org/10.3390/ijms22031062